Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May 18;2(5):269-75.
doi: 10.1021/cn200002t. Epub 2011 Mar 21.

Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains

Masahiro Ono  1 , Shun Hayashi, Kenji Matsumura, Hiroyuki Kimura, Yoko Okamoto, Masafumi Ihara, Ryosuke Takahashi, Hiroshi Mori, Hideo Saji
Affiliations

Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains

Masahiro Ono et al. ACS Chem Neurosci. .

Abstract

A novel series of rhodanin (RH) and thiohydantoin (TH) derivatives were designed and synthesized for detecting tau pathology in the brains of patients with Alzheimer's disease (AD). In experiments in vitro using tau and β-amyloid (Aβ) aggregates, the TH derivative, TH2, showed high specific binding to tau aggregates. In hippocampal sections obtained from AD patients, TH2 intensely stained neurofibrillary tangles. In experiments using normal mice, [(125)I]TH2 showed good uptake (1.54%ID/g, 2 min postinjection) into and a rapid washout (0.25%ID/g, 60 min postinjection) from the brain. [(123)I]TH2 should be further investigated as a potential imaging agent for detecting tau pathology.

Keywords: Alzheimer’s disease; imaging; rhodanine; tau; thiohydantoin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structure of rhodanine and thiohydantoin derivatives reported in this study.
Scheme 1
Scheme 1
Figure 2
Figure 2
Binding of [125I]RH1, [125I]TH1, and [125I]TH2 to tau aggregates and tau monomers.
Figure 3
Figure 3
Comparison of brain uptake of [125I]RH1, [125I]TH1, and [125I]TH2 in normal mice.
Figure 4
Figure 4
In vitro autoradiograms of sections of AD brain labeled with [125I]TH2 (A). The same sections were immunostained using an antibody against hyperphosphorylated tau (AT8) (B).
Figure 5
Figure 5
Neuropathological staining of TH2 in 6 μm sections from the hippocampus of an AD patient (A). The same sections were immunostained using an antibody against hyperphosphorylated tau (AT8) (B).
See this image and copyright information in PMC

References

    1. Selkoe D. J. (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 81, 741–766. - PubMed
    1. Mathis C. A.; Wang Y.; Klunk W. E. (2004) Imaging β-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr. Pharm. Des. 10, 1469–1492. - PubMed
    1. Nordberg A. (2004) PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol. 3, 519–527. - PubMed
    1. Ono M. (2009) Development of positron-emission tomography/single-photon emission computed tomography imaging probes for in vivo detection of β-amyloid plaques in Alzheimer’s brains. Chem. Pharm. Bull. (Tokyo) 57, 1029–1039. - PubMed
    1. Agdeppa E. D.; Kepe V.; Liu J.; Flores-Torres S.; Satyamurthy N.; Petric A.; Cole G. M.; Small G. W.; Huang S. C.; Barrio J. R. (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer’s disease. J. Neurosci. 21, RC189. - PMC - PubMed

Publication types